Company / R&D Expense
Grace Therapeutics, Inc. R&D Expense History
FY2023-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$5.6M
FY2023
5-year range
$5.6M / $5.6M
FY2023-FY2023
Trend
-
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$6M in FY2023.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -0.68 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $5.6M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026